Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a process that is overseen by the Centers for Medicare and Medicaid Services. He said he would focus on fighting chronic disease,

The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input fro | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.